Ahmed Elshafie
Hartford, CTNPI 1043862451
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (56.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Abbott at 59.9% of the total. Reporting peaked in 2023 at $6,693 and has fallen 54.3% since, to $3,055 in 2025.
Across 193 payments — averaging $95.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$11K
- Medtronic$2K
- Boston Scientific$949
- Shockwave Medical, Inc$781
- E.r. Squibb & Sons, L.L.C.$671
- Amgen$492
- plus $3K from 21 others
What the payments were for
- Grants$10,51457%
- Travel & lodging$1,1166%
- Food & beverage$6,89137%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 13 | $11,090 |
| Medtronic | 20 | $1,669 |
| Boston Scientific | 16 | $949 |
| Shockwave Medical, Inc | 7 | $781 |
| E.r. Squibb & Sons, L.L.C. | 25 | $671 |
| Amgen | 24 | $492 |
| AstraZeneca | 11 | $372 |
| Abiomed | 3 | $327 |
| Boehringer Ingelheim | 12 | $242 |
| Pfizer | 12 | $237 |
| Penumbra, Inc. | 2 | $235 |
| Philips North America LLC | 2 | $214 |
| Alnylam Pharmaceuticals Inc. | 4 | $188 |
| Johnson & Johnson | 7 | $147 |
| Actelion Pharmaceuticals US, Inc. | 5 | $146 |
| Edwards Lifesciences | 1 | $144 |
| Bayer | 8 | $130 |
| Novartis | 6 | $118 |
| Lexicon Pharmaceuticals, Inc. | 4 | $95 |
| Merck | 2 | $49 |
| Atricure, Inc. | 1 | $48 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $47 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $43 |
| United Therapeutics Corporation | 1 | $26 |
| Chiesi USA, Inc. | 1 | $24 |
| Imperative Care, Inc | 1 | $20 |
| Inari Medical, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ASSURITY$1,575
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$1,575
- TACTICATH$1,000
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$566
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$260
- ADVISA DR MRI SURESCAN$178
- Ultreon$173
- Indigo System$143
- STINGRAY$133
- CAMZYOS$114
- (6571) Eagle Eye$108
- (6574) Coronary Other$107
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $13,902 |
| XareltoRivaroxaban | 13 | $13,341 |
| Metoprolol Succinate | 55 | $648 |
| Atorvastatin Calcium | 17 | $364 |
| Losartan Potassium | 37 | $345 |
| Rosuvastatin Calcium | 15 | $287 |
| Amlodipine Besylate | 30 | $170 |
| Carvedilol | 14 | $85 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $237 | $13,90214 claims |
| Johnson & JohnsonXarelto | $147 | $13,34113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Connecticuton file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.